The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Open accessAbstract
Standardized criteria for response to therapy in patients with chronic lymphocytic leukemia (CLL), lymphoma, and other malignancies allow for comparisons of outcome between clinical trials and have facilitated regulatory agency approval of novel active agents for use in current standard therapy. In 1988, the National Cancer Institute (NCI) Working Group published the first widely accepted criteria for CLL,1 which were revised in 1996.2 Such recommendations were developed in the context of currently available cytotoxic therapies. Later, in 2008, the International Workshop on CLL published criteria that incorporated much of the 1996 guidelines but also included guidance on how to assess minimal residual disease after therapy.3 These published guidelines defined therapy outcome as either complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), based on surrogate markers of tumor burden, such as blood lymphocyte count, lymph node size, or spleen size, and indicators of improved marrow function or clearance of leukemia cells from the marrow, as assessed by serial blood counts and/or marrow aspirate and biopsy. In general, these response criteria (CR, PR, SD, and PD) in therapeutic trials have correlated with the length of progression-free survival (PFS) and occasionally overall survival after treatment. Because assessment of response using these criteria can often be made years before survival data are available, response criteria have served as useful surrogate markers for assessing the clinical benefit of therapy, thereby accelerating the pace of approval of novel agents for use in the treatment of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Self-citation
Cited by
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationHallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationIbrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817073 · Cited by 749
Self-citationByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
Self-citation
Metadata
- Authors
- Cheson, B. D., Byrd, J. C., Rai, K. R., Kay, N. E., O'Brien, S. M., Flinn, I. W., Wiestner, A., & Kipps, T. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-08-10
- Volume
- 30
- Issue
- 23
- Pages
- 2820-2822
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2134645992
- Cited by
- 192
- References
- 1
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1200/jco.2012.43.3748
- The paper
- Cheson, B. D., Byrd, J. C., Rai, K. R., Kay, N. E., O'Brien, S. M., Flinn, I. W., Wiestner, A., & Kipps, T. J. (2012). Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.3748
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.